The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global alopecia treatment market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 5% during 2021-2026.
Alopecia, also known as hair loss, is an autoimmune skin disease affecting the growth of healthy hair follicles on the scalp, face, and other areas of the body. Its treatment is dependent on numerous factors, including the type of alopecia areata, patient age, and the extent of hair loss. Alopecia treatment aims to block the immune system attack and stimulate the regrowth of hair. Nowadays, phototherapy or low light laser therapy (LLLT) is gaining traction around the world as it is safer, tolerable, and less invasive than other treatments.
As age significantly leads to the gradual thinning of hair, the expanding geriatric population worldwide represents one of the key factors bolstering the market growth. Besides this, stressful lifestyles, the escalating cases of malnutrition, and the rising number of individuals with certain medical conditions, such as diabetes, lupus, and persistent weight loss, are other factors increasing the risk of hair loss. This, along with the growing focus on improving physical health and the increasing access to healthcare services, is positively influencing the need for alopecia treatments across the globe. Moreover, due to the escalating demand for combination therapies with enhanced effectiveness and minimal side effects, cytokine and regenerative cell therapies are widely being used to treat different types of alopecia. Apart from this, several drugs, such as corticosteroid and minoxidil, are available for treating children with alopecia. Additionally, the improving healthcare infrastructure and increasing concerns among parents about the health of their children are contributing to the market growth. Furthermore, a considerable number of drugs are under late-stage clinical trials, which is anticipated to provide a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global alopecia treatment market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug type, indication, gender, route of administration and distribution channel.
Breakup by Drug Type:
Breakup by Indication:
Breakup by Gender:
Breakup by Route of Administration:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aclaris Therapeutics Inc., Cellmid Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, HCell Inc., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Taisho Pharmaceutical Holdings Co. Ltd and Teva Pharmaceutical Industries Ltd.
|Base Year of the Analysis||2020|
|Segment Coverage||Drug Type, Indication, Gender, Route Of Administration, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Aclaris Therapeutics Inc., Cellmid Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, HCell Inc., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Taisho Pharmaceutical Holdings Co. Ltd and Teva Pharmaceutical Industries Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at